← Leaderboards
Keith L Knutson
Mayo Clinic Jacksonville
$7,418,327
Attributed
$11,452,123
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,452,123 · 12
By mechanism
R01$5,758,543 · 3
P50$3,972,200 · 4
K01$741,690 · 1
P30$563,296 · 2
R21$270,540 · 1
R03$145,854 · 1
Top collaborators
- Ellen L. Goode5 shared
- Lynn C. Hartmann5 shared
- Kah-Whye Peng5 shared
- Edith A Perez5 shared
- Raphael A Clynes4 shared
- Matthew Stephen Block3 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Matthew Stephen Block$2,473,112
- Mark E Sherman$5,733,205
Others in their field
Top investigators on “Clinic”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,108,147,906
- Leonard Freedman · Leidos Biomedical Research, Inc.$978,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$798,941,641
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$639,436,363
- Barton F Haynes · Duke University$546,907,423
Research focus
ClinicImmunityMalignant Neoplasm Of OvaryImmune SystemTumorWomanT-LymphocyteProgramsBaseResponseMalignant NeoplasmsImmunotherapyAntibodiesResearch PersonnelImmuneNovel TherapeuticsImmune ResponseCellsGrantPreventCancer PatientOvarian NeoplasmTumor AntigensSite
Grant awards (46)
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer$639,109
R01 · FY2025 · CA · contact PI
Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence$210,820
P50 · FY2025 · CA · contact PI
Cancer Immunology and Immunotherapeutics Research Program$129,625
P30 · FY2025 · CA · contact PI
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer$607,154
R01 · FY2024 · CA · contact PI
Cancer Immunology and Immunotherapy Program$39,235
P30 · FY2024 · CA · contact PI
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer$634,953
R01 · FY2023 · CA · contact PI
Cancer Immunology and Immunotherapy Program$97,967
P30 · FY2023 · CA · contact PI
Cancer Immunology and Immunotherapy Program$98,091
P30 · FY2022 · CA · contact PI
Cancer Immunology and Immunotherapy Program$97,967
P30 · FY2021 · CA · contact PI
Cancer Immunology and Immunotherapy Program$100,411
P30 · FY2020 · CA · contact PI
Project 8 - TH17 Dendritic Cell Vaccine$340,613
P50 · FY2019 · CA · contact PI
Project 8 - TH17 Dendritic Cell Vaccine$306,610
P50 · FY2018 · CA · contact PI
Project 8 - TH17 Dendritic Cell Vaccine$306,631
P50 · FY2017 · CA · contact PI
Project 8 - TH17 Dendritic Cell Vaccine$280,591
P50 · FY2016 · CA · contact PI
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$534,720
R01 · FY2015 · CA
Project 8 - TH17 Dendritic Cell Vaccine$265,812
P50 · FY2015 · CA · contact PI
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$521,566
R01 · FY2014 · CA
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$511,906
R01 · FY2013 · CA
Mechanisms of Immune Suppression in Ovarian Cancer$209,136
P50 · FY2013 · CA · contact PI
Animal Models$171,968
P50 · FY2013 · CA · contact PI
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$549,804
R01 · FY2012 · CA
Mechanisms of Immune Suppression in Ovarian Cancer$327,530
P50 · FY2012 · CA · contact PI
Animal Models$171,472
P50 · FY2012 · CA · contact PI
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$619,306
R01 · FY2011 · CA
Mechanisms of Immune Suppression in Ovarian Cancer$264,989
P50 · FY2011 · CA · contact PI
Animal Models$178,889
P50 · FY2011 · CA · contact PI
Mechanisms of Immune Suppression in Ovarian Cancer$279,645
P50 · FY2010 · CA · contact PI
Animal Models$188,653
P50 · FY2010 · CA · contact PI
Mechanisms of Immune Suppression in Ovarian Cancer$279,974
P50 · FY2009 · CA · contact PI
HLA classl complex expression in breast cancer immunity$221,806
R01 · FY2009 · CA · contact PI
Animal Models$188,867
P50 · FY2009 · CA · contact PI
HLA class l complex expression in breast cancer immunity$221,806
R01 · FY2008 · CA · contact PI
Ex vivo expansion of HER-2/neu specific T helper cells$152,658
K01 · FY2008 · CA · contact PI
HLA class l complex expression in breast cancer immunity$221,806
R01 · FY2007 · CA · contact PI
Ex vivo expansion of HER-2/neu specific T helper cells$152,658
K01 · FY2007 · CA · contact PI
Analysis of serum folate receptor and antibody level for ovarian cancer detection$71,854
R03 · FY2007 · CA · contact PI
HLA classl complex expression in breast cancer immunity$228,430
R01 · FY2006 · CA · contact PI
Ex vivo expansion of HER-2/neu specific T helper cells$152,658
K01 · FY2006 · CA · contact PI
Analysis of serum folate receptor and antibody level for ovarian cancer detection$74,000
R03 · FY2006 · CA · contact PI
HLA class l complex expression in breast cancer immunity$246,177
R01 · FY2005 · CA
Ex vivo expansion of HER-2/neu specific T helper cells$152,658
K01 · FY2005 · CA
Tumor rejection antigens induced via epitope spreading$134,100
R21 · FY2005 · CA
Tumor rejection antigens induced via epitope spreading$102,216
R21 · FY2004 · CA
Ex vivo expansion of HER-2/neu specific T helper cells$98,942
K01 · FY2004 · CA
Tumor rejection antigens induced via epitope spreading$34,224
R21 · FY2004 · CA
Ex vivo expansion of HER-2/neu specific T helper cells$32,116
K01 · FY2004 · CA